Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from the U.S. Food and Drug Administration (FDA) for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with prostate adenocarcinoma. With this approval, patients identified with PTEN deficiency may now be eligible for treatment with AstraZeneca's targeted therapy TRUQAP (capivasertib).
The VENTANA PTEN (SP218) RxDx Assay is a qualitative immunohistochemical test designed to assess PTEN protein in prostate adenocarcinoma. Using the OptiView DAB IHC Detection Kit for staining on the BenchMark ULTRA instrument, the assay serves as an aid in identifying patients who may benefit from TRUQAP in combination with abiraterone acetate, in line with the approved therapeutic product labeling.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.